thymosin alpha-1 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-06-20. Anything still debated is marked as such rather than presented as settled.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.
Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 3,108 Da | Consistent with a 28-residue acetylated peptide |
| Residue count | 28 | Corresponds to the amino terminal region of prothymosin alpha |
| Appearance of dry powder | White to off-white solid | Slight variation between lots is normal |
| Solubility class | Freely soluble in water | Low solubility in most organic solvents |
| Common synonyms | Thymosin alpha 1, T alpha 1 | The numeral reflects an early fraction numbering scheme |
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography, which separates the peptide from closely related impurities and from truncated or oxidized variants. Mass spectrometry supplies the molecular mass and confirms the expected sequence length, while amino acid analysis can be used to check composition. Because the molecule has no chromophore beyond the peptide backbone, ultraviolet detection is typically performed at a low wavelength, where baseline interference from solvents and buffers is a practical concern. Water content and counter-ion content are often reported alongside purity.
Practical handling focuses on limiting adsorption and contamination. The peptide dissolves readily in water, and dilute solutions tend to adhere to plastic and glass surfaces, so an inert carrier protein or a defined buffer can reduce losses in laboratory work. Workers also record the counter-ion form, since an acetate or trifluoroacetate salt changes the mass balance of the weighed powder. Documentation of lot number, purity value, and storage history supports reproducibility when results from different laboratories are compared.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
A 2020 review found most men believed the average erect penis length is more than 15.24 cm (6 inches). This inaccurate belief has likely been fed by inaccurate and exaggerated data presented in studies where the size of a participant's erect penis is self-reported. Participants may report overestimates of the size of their penis in the belief that a larger penis is more socially desirable. The same review analyzed the results from ten prior studies where measurements of erect penis size were made by researchers. They reported an erect penis to be between 12.95 and 13.92 cm (5.1 and 5.5 inches, respectively) in length, a result significantly below the average obtained in self-reported studies. The authors commented that results of such measurement studies may still be inflated due to volunteer bias — the possibility that men with larger penises may be more likely to choose to participate in such studies.
General Sir John French, General Officer Commanding the BEF, later wrote 'Without the assistance which the Territorials afforded between October 1914 and June 1915, it would have been impossible to hold the line in France and Belgium. Other Territorial formations were dispatched to Egypt and British India and other imperial garrisons, such as Gibraltar, thereby releasing regular units for service in France and enabling the formation of an additional five regular army divisions by early 1915. Territorial divisions went on to fight in all the major battles of the war in France and Belgium and several campaigns further afield including Gallipoli. (See main article Territorial Force). From 1916, as the war progressed, and casualties mounted, the distinctive character of territorial units was diluted by the inclusion of conscript and New Army drafts. Following the Armistice all units of the Territorial Force were gradually disbanded.
Glutathione S-transferase omega-1 is an enzyme that in humans is encoded by the GSTO1 gene. This gene encodes a member of the theta class glutathione S-transferase-like (GSTTL) protein family. In mouse, the encoded protein acts as a small stress response protein, likely involved in cellular redox homeostasis. This protein has dehydroascorbate reductase activity and may function in the glutathione-ascorbate cycle as part of antioxidant metabolism.
Sources: en.wikipedia.org
== History == Myelofibrosis was first described in 1879 by Gustav Heuck. Eponyms for the disease are Heuck-Assmann disease or Assmann's Disease, for Herbert Assmann, who published a description under the term "osteosclerosis" in 1907. It was characterised as a myeloproliferative condition in 1951 by William Dameshek. The disease was also known as myelofibrosis with myeloid metaplasia and agnogenic myeloid metaplasia The World Health Organization utilized the name chronic idiopathic myelofibrosis until 2008, when it adopted the name of primary myelofibrosis. In 2016, the WHO revised their classification of myeloproliferative neoplasms to define Prefibrotic primary myelofibrosis as a distinct clinical entity from overt PMF.
Sinosauropteryx (meaning "Chinese reptilian wing") is an extinct genus of coelurosaurian theropod dinosaurs. Described in 1996, it was the first dinosaur taxon outside of Avialae (birds and their immediate relatives) to be found with evidence of feathers. It was covered with a coat of very simple filament-like feathers. Structures that indicate the colour pattern have also been preserved in some of its feathers, which show that Sinosauropteryx had a countershading pattern in its body with a banded tail. The reddish brown colouration previously inferred for Sinosauropteryx is based on the melanosomes preserved in the specimen of a separate genus, Huadanosaurus. Some contention has arisen with an alternative interpretation of the filamentous impression as remains of collagen fibres, but this has not been widely accepted. Sinosauropteryx was a small theropod with an unusually long tail and short arms. The longest known specimen reaches up to 1.07 metres (3.51 feet) in length, with an estimated weight of 0.55 kilograms (1.21 pounds). It was considered a close relative of the similar but older genus Compsognathus, with both genera belonging to the family Compsognathidae, though subsequent analyses did not recover this family to be monophyletic and placed Sinosauropteryx within its own family, Sinosauropterygidae. Two species of Sinosauropteryx have been named. The first, S. prima, is known from three specimens, named "first" in reference to its status as the first feathered non-avian dinosaur species discovered.
Collagen alpha-5(IV) chain is a protein that in humans is encoded by the COL4A5 gene. This gene encodes one of the six subunits of type IV collagen, the major structural component of basement membranes. Mutations in this gene are associated with X-linked Alport syndrome, also known as hereditary nephritis. Like the other members of the type IV collagen gene family, this gene is organized in a head-to-head conformation with another type IV collagen gene so that each gene pair shares a common promoter. Three transcript variants have been identified for this gene.
Sources: en.wikipedia.org
=== Liver disease === Liver fibrosis and cirrhosis are associated with the deposition of collagen IV in the liver. Serum collagen IV concentrations correlate with hepatic tissue levels of collagen IV in subjects with alcoholic liver disease and hepatitis C and fall following successful therapy.
== History == First published synthesis and report of properties of fluorine-18 were in 1937 by Arthur H. Snell, produced by the nuclear reaction of 20Ne(d,α)18F in the cyclotron laboratories of Ernest O. Lawrence.
Prokaryotes and yeast are relatively easy to freeze-dry and then resuscitate. In bacteriology freeze-drying is used to conserve special strains. Dry powders of probiotics are often produced by bulk freeze-drying of live microorganisms such as lactic acid bacteria and bifidobacteria. Live vaccines (described above) are also examples of this class. The simpler blood cells (red blood cells and platelets) have been freeze-dried. With the right protection, recovery rates are as high as 90%. Spermatozoa are relatively resistant to freeze-drying. Even highly-damaged cells can initiate embryonic development, though direct injection into the egg may be needed. Mouse sperm freeze-dried without any protection has produced live offspring. General animal cells are relatively fragile, but trehalose has proven effective in protecting Drosophilia and many lines of mammalian cells during freeze-drying. Even if the cell is damaged beyond resuscitation, it is preserved. This can be helpful for later research too: although the type strain culture for Vampirovibrio chlorellavorus could not be resuscitated, it contained enough DNA for its genome to be sequenced.
==== Road to war ==== Liu Wenhui's 1990 biography asserts that conflict between the two Lius was almost inevitable. Due to the consolidation of power in Sichuan that had occurred over the 1920s, Liu Wenhui and Liu Xiang had become the two most powerful warlords in the province. Liu Wenhui's assumption of the governorship in 1929 had turned many smaller warlords against him. By controlling the lower reaches of the Yangtze and the Qutang Gorge, Liu Xiang held the geographic advantage over his uncle, having priority in purchasing weapons from abroad (which entered Sichuan through the Yangtze), and had built a navy of three gunboats by fitting merchant ships with iron hulls. This also meant that Liu Xiang could block weapons from reaching Liu Wenhui's upstream domains, an ability that he would use to his advantage. Liu Xiang was also reportedly under the sway of his Taoist mystic advisor, Liu Congyun, who had told him that he was destined to unite the province under his rule. Yet another supposed factor contributing to conflict was the interference of Chiang Kai-shek, who did not want either warlord to become too powerful. Most sources agree that Liu Wenhui's abortive attempt to acquire military aviation assets in 1931 was the spark that led him to conflict with his nephew. Official Chinese sources state that a shipment ordered by Liu of foreign aircraft components worth 2 million yuan was seized by Liu Xiang at the port of Wanxian in Chongqing, leading to heightened tensions between the two Lius.
Sources: en.wikipedia.org
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.
It is a 28-amino-acid peptide originally purified from a bovine thymic extract and later produced synthetically. It is studied mainly for its effects on immune cell function.
No. The two peptides share part of a name but differ in length, sequence, and net charge. Literature searches that treat them as one compound return misleading results.
Solid-phase peptide synthesis is the usual route, and recombinant expression has also been described. Both approaches produce material matching the natural sequence.